Newsroom

Featured

Alvotech enrolls first patient in clinical phase III study

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®

  • Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors

Read More
MEET THE MANAGEMENT

Highly experienced management team with a proven track record of achieving high...

Media Gallery

Download center for company logos and images.

News alert

Enter your email to sign up for news alerts

MEDIA CONTACT

Halldor Kristmannsson 
Vice President
Organizational Development
Global Communications & Branding

Phone (354) 522-2900

Email
Connect on LinkedIn

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.